PANTHERx Rare Collaborates with Otsuka for New Therapy
PANTHERx Rare Pharmacy proudly announces its selection by Otsuka as the exclusive specialty pharmacy to dispense VOYXACT® (sibeprenlimab-szsi). This innovative treatment targets adults suffering from primary immunoglobulin A nephropathy (IgAN) and aims to significantly reduce proteinuria, which is a key indicator of the disease.
About VOYXACT and Its Approval
VOYXACT® has received accelerated approval for its ability to lower proteinuria levels in patients at risk of disease progression. However, it remains unclear if VOYXACT slows the long-term decline of kidney function in those living with IgAN. This unique therapy is an APRIL (A Proliferation Inducing Ligand) blocker, highlighting the evolving landscape of treatment options available for this condition.
PANTHERx Commitment to Personalized Care
Bansi Nagji, CEO of PANTHERx Rare Pharmacy, expressed enthusiasm about this partnership, stating, "Our relationship with Otsuka has flourished since 2018. We are dedicated to offering hyper-personalized care tailored to each patient’s experience with IgAN. This new therapy marks an exciting breakthrough, and we are honored to facilitate access for those in need." This collaborative spirit demonstrates PANTHERx's commitment to advocating for patients through innovative care strategies.
About PANTHERx Rare and Its Achievements
Founded in Pittsburgh in 2011, PANTHERx has transformed the rare disease care landscape, becoming the largest independent rare pharmacy in the United States. With a focus on building strong relationships with patients, prescribers, and pharmaceutical partners, PANTHERx fosters a supportive environment ensuring seamless care. Their reputation is bolstered by being the first national pharmacy to achieve dual accreditations in rare disease management from relevant committees.
Licensing and Recognition
PANTHERx holds licenses in all 50 states and U.S. territories. The pharmacy has earned the prestigious MMIT Patient Choice Award eight times, including the most recent accolade showcasing their commitment to patient satisfaction in 2025.
Understanding Immunoglobulin A Nephropathy
Immunoglobulin A Nephropathy (IgAN), commonly referred to as Berger disease, is characterized by the accumulation of IgA in the kidneys, leading to inflammation and damage. This condition can result in various complications, including high blood pressure and chronic kidney disease.
Symptoms and Complications of IgAN
Patients with IgAN may experience symptoms such as blood in the urine (hematuria), protein leakage leading to foamy urine (proteinuria), and swelling in limbs due to excess fluid (edema). While these symptoms may take years to become apparent, the potential complications can severely impact quality of life.
Conclusion and Future Directions
PANTHERx Rare Pharmacy remains a significant player in the evolving treatment landscape of rare diseases. Through its partnership with Otsuka and dedication to personalized care, the company promises to enhance patient experiences and outcomes in managing IgAN.
Frequently Asked Questions
What is VOYXACT used for?
VOYXACT is used to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
How does PANTHERx Rare support patients?
PANTHERx Rare provides personalized care and support services, ensuring that each patient receives tailored treatment and advocacy throughout their healthcare journey.
When was PANTHERx Rare founded?
PANTHERx Rare was founded in 2011 in Pittsburgh, Pennsylvania, and has since grown to become the largest independent rare pharmacy in the U.S.
What are the symptoms of immunoglobulin A nephropathy?
Symptoms of IgAN include hematuria, foamy urine due to proteinuria, and edema in the legs and ankles.
What awards has PANTHERx Rare received?
PANTHERx Rare has received the MMIT Patient Choice Award multiple times for outstanding patient satisfaction, most recently in 2025.
